News

Adial Pharmaceuticals Announces Third-Party Sales and Distribution Agreement with Brik for Rapid Result COVID-19 Antibody Test Kits

CHARLOTTESVILLE, VA / ACCESSWIRE / August 6, 2020 / Adial Pharmaceuticals, Inc.

08/06/2020

Adial Pharmaceuticals Schedules Business and Clinical Update Conference Call

Developments to be Shared by Dr.

07/28/2020

Profitability

Gross Profit Margin	0 %
Net Income Per EBT	100 %
Net Profit Margin	0 %
Return on Assets	-261.65 %
Return on Equity	-259.41 %

Dividends

Dividend Yield (FWD)	Nil
Dividend Per Share	Nil
Payout Ratio	Nil
Payout Date	Nil
Ex-Dividend Date	Nil
Latest Announced Dividend	Nil

Income Statement

Revenue	$0B
Gross Profit	$0B
Gross Profit Ratio	0%
EBITDA	$-0.01B
Net Income	$-0.01B
EPS Diluted	-0.71

Balance Sheet

Long Term Debt	$0B
Total Liabilities	$0B
Total Equity	$0B
Total Investments	$0B
Total Debt	$0B
Total Assets	$0.01B

Cash Flow Statement

Net Income	$-0.01B
Inventory	$0B
Dividends Paid	$0B
Operating Cash Flow	$-0.01B
Capital Expenditure	$0B

Symbol Frequently Asked Questions

Is Adial Pharmaceuticals, Inc. WT EXP 073123 (ADILW) a buy, sell, or hold?

Adial Pharmaceuticals, Inc. WT EXP 073123 (ADILW) can sell. Click on Rating Page for detail.

What is Adial Pharmaceuticals, Inc. WT EXP 073123's stock price?

The price of Adial Pharmaceuticals, Inc. WT EXP 073123 (ADILW) is 0.0009 and it was updated on 2025-04-06 07:01:40.

Is Adial Pharmaceuticals, Inc. WT EXP 073123 (ADILW) overvalued or undervalued?

Currently Adial Pharmaceuticals, Inc. WT EXP 073123 (ADILW) is in undervalued.

News

From:

To:

Show entries

Search:

News
Adial Pharmaceuticals Receives European Medicines Agency (EMA) Agreement on the Pediatric Investigation Plan (PIP) for AD04 in Alcohol Use Disorder EMA Agreement paves the way for a marketing authorization in Europe after Phase 3CHARLOTTESVILLE, VA / ACCESSWIRE / July 22, 2020 / Adial Pharmaceuticals, Inc. Wed, Jul. 22, 2020
Adial Pharmaceuticals Announces Approval to Commence Landmark ONWARD(TM) Pivotal Phase 3 Trial in Sweden and Estonia CHARLOTTESVILLE, VA / ACCESSWIRE / July 6, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL:ADILW) ("Adial"), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it has received approvals in Sweden and Estonia to commence the Company's landmark ONWARD™ pivotal Phase 3 clinical trial to investigate its lead drug candidate, AD04, as a therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in persons with certain target genotypes related to the serotonin transporter and receptor genes. The Swedish Medical Products Agency and Swedish Ethical Review Authority have provided approval for ONWARD™ to commence in Sweden; and the Estonian State Agency of Medicines and Ethics Review Committee overseeing human trials granted approval to commence ONWARD™ in Estonia. Mon, Jul. 06, 2020
Adial Pharmaceuticals Announces Commencement of Landmark ONWARD(TM) Pivotal Phase 3 Trial in Poland CHARLOTTESVILLE, VA / ACCESSWIRE / June 25, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) ("Adial"), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it has commenced its landmark ONWARD™ pivotal Phase 3 clinical trial in Poland to investigate its lead drug candidate, AD04, as a therapeutic agent for the treatment of Alcohol Use Disorder in persons with certain target genotypes related to the serotonin transporter and receptor genes. "We are pleased to announce we were able to begin the trial less than two weeks after we received approval from Poland's Office for Registration of Medicinal Products, Medical Devices and Biocidal Products and the relevant regional Polish ethics committees overseeing the trial," commented William Stilley, Chief Executive Officer of Adial Pharmaceuticals. Thu, Jun. 25, 2020
Adial Pharmaceuticals Announces Commencement of the Landmark ONWARD(TM) Pivotal Phase 3 Clinical Trial in Latvia CHARLOTTESVILLE, VA / ACCESSWIRE / June 17, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) ("Adial"), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it has opened clinical trial sites and is recruiting trial subjects in Latvia after receiving all necessary approvals to commence the landmark ONWARD™ pivotal Phase 3 clinical trial in Latvia, including from the State Agency of Medicines of the Republic of Latvia and the Latvian Central Ethics Committee. The ONWARD™ trial is investigating Adial's lead drug candidate, AD04, as a therapeutic agent for the treatment of Alcohol Use Disorder in persons with certain target genotypes related to the serotonin transporter and receptor genes. Wed, Jun. 17, 2020
Adial Pharmaceuticals Closes Previously Announced $5.2 Million Registered Direct Offering CHARLOTTESVILLE, VA / ACCESSWIRE / June 15, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) ("Adial" or the "Company"), a biopharmaceutical company focused on the development of treatments for addiction and currently conducting the ONWARD™ pivotal Phase 3 clinical trial of its lead drug candidate, AD04, for the treatment of Alcohol Use Disorder, today announced the closing on June 11,2020 of its previously announced registered direct offering of 2,820,000 shares of its common stock at a purchase price of $1.85 per share for gross proceeds of $5,217,000 priced at-the-market under Nasdaq rules. In a concurrent private placement, Adial also issued warrants to purchase 2,115,000 shares of common stock, which warrants are immediately exercisable, will expire 5 years from the date of issuance and will have an exercise price of $2.00 per share of common stock. Mon, Jun. 15, 2020

Showing 1 to 5 of 5 entries

Previous1Next

SEC Filings

Show entries

Search:

SEC Filings
Adial Pharmaceuticals, Inc. WT EXP 073123 (ADILW) - 8-K - Current report SEC Filings 03/07/2025
Adial Pharmaceuticals, Inc. WT EXP 073123 (ADILW) - 8-K - Current report SEC Filings 03/04/2025
Adial Pharmaceuticals, Inc. WT EXP 073123 (ADILW) - 10-K - Current report SEC Filings 03/04/2025
Adial Pharmaceuticals, Inc. WT EXP 073123 (ADILW) - 8-K - Current report SEC Filings 02/25/2025
Adial Pharmaceuticals, Inc. WT EXP 073123 (ADILW) - 8-K - Current report SEC Filings 01/13/2025
Adial Pharmaceuticals, Inc. WT EXP 073123 (ADILW) - 8-K - Current report SEC Filings 01/08/2025
Adial Pharmaceuticals, Inc. WT EXP 073123 (ADILW) - EFFECT SEC Filings 12/31/2024
Adial Pharmaceuticals, Inc. WT EXP 073123 (ADILW) - 424B3 SEC Filings 12/31/2024
Adial Pharmaceuticals, Inc. WT EXP 073123 (ADILW) - S-1 SEC Filings 12/20/2024
Adial Pharmaceuticals, Inc. WT EXP 073123 (ADILW) - 8-K - Current report SEC Filings 12/18/2024

Showing 1 to 10 of 393 entries

Previous1 2 3 4 5…40Next

More Headlines

Show entries

Search:

News
Adial Pharmaceuticals Announces Approval to Commence Landmark ONWARD(TM) Pivotal Phase 3 Trial in Poland CHARLOTTESVILLE, VA / ACCESSWIRE / June 11, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) ("Adial"), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it has received all necessary approvals to commence its landmark ONWARD™ pivotal Phase 3 clinical trial in Poland to investigate its lead drug candidate, AD04, as a therapeutic agent for the treatment of Alcohol Use Disorder in persons with certain target genotypes related to the serotonin transporter and receptor genes. This includes the receipt of approvals from both the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products and the relevant regional Polish Ethics Committees overseeing the trial. 06/11/2020
Adial Pharmaceuticals Receives Order for 1,000 COVID-19 Antibody Test Kits CHARLOTTESVILLE, VA / ACCESSWIRE / June 10, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) ("Adial"), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it has received an initial firm order for the purchase of 1,000 Rapid Result COVID-19 antibody test kits. The customer intends to utilize the test kits for understanding exposure to the virus in the City of Phoenix, Arizona and surrounding communities and to advance efforts to protect the health and safety of frontline workers. 06/10/2020
Adial Pharmaceuticals Announces Pricing of $5.2 Million Registered Direct Offering Priced At-The-Market CHARLOTTESVILLE, VA / ACCESSWIRE / June 9, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) ("Adial" or the "Company"), a biopharmaceutical company focused on the development of treatments for addiction and currently conducting the ONWARD™ pivotal Phase 3 clinical trial of its lead drug candidate, AD04, for the treatment of Alcohol Use Disorder, today announced that it has entered into a securities purchase agreement with institutional investors to purchase approximately $5.2 million of its common stock in a registered direct offering priced at-the-market under Nasdaq rules and warrants to purchase common stock in a concurrent private placement. The combined purchase price for one share of common stock and a warrant to purchase 0.75 shares of common stock will be $1.85. 06/09/2020
Adial Pharmaceuticals and BioLab Sciences Enter into Distribution Agreement for COVID-19 Antibody Tests Antibody Testing Available for Landmark ONWARD (TM) Pivotal Phase 3 Trial Participants BioLab Sciences Grants Adial Exclusive Rights to Sell and Distribute Rapid Result COVID-19 Antibody Tests to Designated ... 06/08/2020
Adial Pharmaceuticals Appoints Dr. Jack Reich to Board of Directors CHARLOTTESVILLE, VA / ACCESSWIRE / May 28, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced the appointment of Dr. Jack Reich to the Board of Directors. Dr. Reich will serve on the Audit Committee as well as the Nominations and Corporate Governance Committee. 05/28/2020
Op-Ed by Adial Pharmaceuticals CEO Published in the Daily Progress CHARLOTTESVILLE, VA / ACCESSWIRE / May 4, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) , a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, announced ... 05/04/2020
Adial Pharmaceuticals Files Post-Effective Amendments to Registration Statements For Outstanding Shares Underlying Existing Warrants and Shelf Registration Statement to Provide Financial Flexibility CHARLOTTESVILLE, VA / ACCESSWIRE / April 23, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) , a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, ... 04/23/2020
Adial Pharmaceuticals Provides Update on ONWARD(TM) Phase 3 Pivotal Trial CHARLOTTESVILLE, VA / ACCESSWIRE / April 9, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today provided an update on its landmark ONWARD™ Phase 3 pivotal trial of its lead drug candidate, AD04, in genetically identified subjects for the treatment of Alcohol Use Disorder (AUD). The number of in-clinic visits per subject has been reduced from 19 to 8. 04/09/2020
Adial Pharmaceuticals Receives Issue Notification for Patent Covering AD04 for the Treatment of Opioid Use Disorder CHARLOTTESVILLE, VA / ACCESSWIRE / March 26, 2020 / Adial Pharmaceuticals, Inc. (ADIL)(ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it received an Issue Notification for the issuance of a patent by the United States Patent and Trademark Office (USPTO) for the treatment of Opioid Use Disorder (OUD) with its lead drug candidate, AD04, in people that are positive for select genotypes identified using the Company's propriety companion genetic test. Including the patent term adjustment provided in the Issue Notification, the patent is expected to provide commercial exclusivity for AD04 until September 2031, plus potential Hatch-Waxman extensions. 03/26/2020
Adial Pharmaceuticals Announces Modifications to the Phase 3 Pivotal Trial of AD04 to Protect Subjects from COVID-19 CHARLOTTESVILLE, VA / ACCESSWIRE / March 17, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that, effective immediately, the Company is modifying its pivotal Phase 3 clinical trial of the Company's lead drug candidate, AD04, for the treatment of alcohol use disorder (AUD) in genetically targeted patients. In order to better protect subjects enrolled in the Phase 3 clinical trial during the COVID-19 pandemic, the Company is in the process of modifying its protocol to reduce the number of in-person visits to clinical sites and replace certain visits with tele-medicine behavioral treatments and assessments. European regulators have encouraged sponsors of clinical trials to take action to reduce travel and potential exposure of study subjects and have indicated receptivity to modifications that achieve this end. 03/17/2020

Showing 1 to 10 of 16 entries

Previous1 2Next

Unlock

ADILW Ratings Summary

Quant

Sell

ADILW Quant Ranking

Quant Rating	Sell
Quant Score	2

Is Adial Pharmaceuticals, Inc. WT EXP 073123 (ADILW) a buy, sell, or hold?

What is Adial Pharmaceuticals, Inc. WT EXP 073123's stock price?

Is Adial Pharmaceuticals, Inc. WT EXP 073123 (ADILW) overvalued or undervalued?

Adial Pharmaceuticals Announces Approval to Commence Landmark ONWARD(TM) Pivotal Phase 3 Trial in Poland

Adial Pharmaceuticals Receives Order for 1,000 COVID-19 Antibody Test Kits

Adial Pharmaceuticals Announces Pricing of $5.2 Million Registered Direct Offering Priced At-The-Market

Adial Pharmaceuticals and BioLab Sciences Enter into Distribution Agreement for COVID-19 Antibody Tests

Adial Pharmaceuticals Appoints Dr. Jack Reich to Board of Directors

Op-Ed by Adial Pharmaceuticals CEO Published in the Daily Progress

Adial Pharmaceuticals Files Post-Effective Amendments to Registration Statements For Outstanding Shares Underlying Existing Warrants and Shelf Registration Statement to Provide Financial Flexibility

Adial Pharmaceuticals Provides Update on ONWARD(TM) Phase 3 Pivotal Trial

Adial Pharmaceuticals Receives Issue Notification for Patent Covering AD04 for the Treatment of Opioid Use Disorder

Adial Pharmaceuticals Announces Modifications to the Phase 3 Pivotal Trial of AD04 to Protect Subjects from COVID-19

Company Details

Ratings

Quant Factor Grades

Trading

Dividend Grades

Dividend

Earnings

Valuation

Growth

Performance

Momentum

Profitability

Risk

Ownership

Debt